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Introduction
Contrast agents (CAs) containing paramagnetic agents,used in magnetic resonance imaging (MRI), are non
invasive and powerful diagnostic tools in cancer early
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Abstract
Purpose: Early cancer diagnosis using MRI imaging is of high global interest as a non-invasive and
powerful modality. In this study, methionine was conjugated on gadolinium-basedmesoporous silica
nanospheres to evaluate intra-cellular uptake and its accumulation in human breast cancer cells.
Procedures: The contrast agent was synthesized and characterized using different techniques
including N2 physisorption, thermal gravimetric analysis, dynamic light scattering, and
inductively coupled plasma atomic emission spectroscopy (ICP-AES). The intra-cellular uptake
of Gd3+ was measured by ICP-AES, ﬂuorescent microscopy, and ﬂow cytometry. Finally,
cellular and tumor MR imaging were performed to determine in vitro and in vivo relaxometry.
Results: According to the results, the contrast agents accumulated in tumor cells both in vitro
and in vivo. There was no signiﬁcant cellular toxicity on either normal or cancer cells along with
strong intense signal on T1 compared to the unlabeled cells.
Conclusions: The results showed that the novel contrast agent could become a useful tool in
early detection of cancer.
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diagnosis and biomedical research due to their ability to
provide high-resolution anatomical images of soft and in-
depth anatomical tissues. Metal ions (predominantly gado-
linium ions, Gd3+) are widely used to improve the diagnostic
conﬁdence in MRI [1]. These CAs exhibit time-dependent
magnetic dipolar interaction with the surrounding water
protons and improve the MRI sensitivity by decreasing the
proton relaxation time T1 [2, 3]. However, currently used
CAs are mainly small gadolinium chelate molecules with a
lack of sensitivity and often do not provide suitable contrast
enhancement in early cancer stages [1]. Despite progress in
design and preparation of CAs, many of them are still
limited by low speciﬁcity, selectivity, and toxicity [1]. To
overcome these limitations, it is necessary to accumulate a
large number of CAs at the target site by recognizing
speciﬁc molecules that are over expressed in the given
pathological area [3]. Recent advances in nanotechnology
have improved the properties of CAs for these biomedical
applications [4]. Among nanoparticles, porous materials are
ideal platforms for a large number of CAs imaging due to
their high-surface area and porosity. Mesoporous silica
nanospheres (MSN) have high-surface area and high-pore
volume. They also have internal surface (i.e., cylindrical
pores) and external surface (i.e., exterior particle surface)
[5]. MSNs are comprised of a honeycomb-like porous
structure with hundreds of empty channels that are able to
encapsulate relatively large amounts of CAs. These charac-
teristics allow selective functionalization of the internal and/
or external surfaces of MSNs with different moieties. In
addition, attaching a target group such as antibodies,
peptides, aptamers, carbohydrate, e.g., glucose [6] and folic
acid [7] on the surface of MSN can be used to increase the
speciﬁc accumulation of these nanoparticles within the
desired cancerous tissue or on its surface. Amino acids are
one of these target groups [8, 9]. Additionally, a signiﬁcant
glutamine uptake by the cancerous cells has been reported
[3, 9–11]. Tumor cells have an increased demand for amino
acids compared to normal cells [3, 8–11]. In fact, prolifer-
ating cells consume more methionine (and its derivatives)
than their normal cells [12, 13].
Amino acid uptake is increased in tumor, which is often
exploited for tumor detection and staging and to assess
therapeutic treatment, using radiolabeled amino acids such
as methionine [12] by single-photon emission computed
tomography or positron emission tomography techniques
[10–13]. Methionine is an essential amino acid which is
necessary for growth and development; since proliferating
cancer cells absorb more methionine, it is transported into
cancer cells faster than normal cells [11]. Many studies have
reported using liposomes and nanoparticles labeled with
Gd3+ complexes targeted to amino acid transporters in order
to image the tumor angiogenesis [14–16].
In this study, we introduce a novel Gd3+-based contrast
agent for cancer cell imaging. Our study focuses on the
exploitation of the methionine transport system in order to
incorporate Gd3+-based mesoporous silica nanospheres
conjugated with methionine (Met-MSNs-Gd3+) into the
cancer cells. Therefore, we report here the synthesis,
physicochemical analysis, application of Met-MSNs-Gd3+,
as well as in vitro and in vivo studies, along with cellular
uptake behavior and its application in MRI cell imaging.
Materials and Methods
Chemical
Fetal bovine serum (FBS), penicillin sterptomycin and GdCl3.6H2O
(99 %) and Chelex 100 (Na+ form) were purchased from Sigma
Aldrich Co. (USA), aminopropyltriethoxysilane (APTES, 99 %),
tetraethyl orthosilicate (TEOS, 98 %), anhydrous ethanol (EtOH,
99.5 %), cetyltrimethylammonium bromide (CTAB, 98%), 3-
(trimethoxysilylpropyl) diethylenetriamine (99.9 %), sodium hy-
droxide, anhydrous N, N-dimethyl formamide (DMF, 99.8 %), and
toluene (99.8 %) provided from Acros Co. (Belgium) and used
without further puriﬁcation. Dialysis bag with 500–1,000 Da cut off
obtained from the Spectrum Lab. (USA). Magnevist® obtained
from Bayer HealthCare Pharmaceuticals Inc., (Montville, NJ,
USA). Other materials were purchased from Merck KGaA
(Darmstadt, Germany).
Human breast cancer cell lines (MCF-7), human kidney cell line
(HEK 293) and murine mammary adenocarcinoma cells (derived
from M05 cell line) were provided from National Cell Bank of
Pasteur Institute of Iran.
Animals
All the animal studies have been conducted according to relevant
national and international guidelines of Tehran University of
Medical Sciences. All inbred female BALB/c mice (6–8 weeks
old, purchased from Iran Pasteur Institute) were maintained in large
group houses under 12-h dark and light cycles, and were given
access to food and water ad libitum.
Synthesis of Gd3+-Based Mesoporous Silica
Nanoparticles
The MSN were synthesized according to the Stober method [2, 17].
Brieﬂy, CTAB (1.0 g) was dissolved in distilled water (480.0 ml)
which contained NaOH (4.0 ml, 2 M) and the solution was heated
at 80 °C. TEOS (5.0 ml) was added drop wise over 15 min to the
mixture. After stirring for 3 h at 80 °C, MSN were isolated by
ﬁltration and washed twice with distilled water and ethanol.
Silanization of Mesoporous Silica Nanoparticles
(MSN-NH2)
MSN (1.0 g) were dispersed in anhydrous ethanol (100 ml) and
sonicated for 10 min. APTES (1.0 ml) was added to the
solution in approximately 15 min and the reaction was stirred
for 12 h. The resulting solution was centrifuged at 5,000 rpm
for 25 min and residues were redispersion in water to remove
unreacted APTES [17].
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Surfactant Extraction
CTAB template was extracted from MSN-NH2 (1.0 g) by HCl
(5.0 ml) in ethanol (120.0 ml) under reﬂux. After 12 h, the
reaction mixture was centrifuged at 6,000 rpm for 25 min at
RT. The extracted MSN-NH2 was washed three times with
ethanol and was stored as dispersion in ethanol (96 %) for
further usage [17].
Si-DTPA Complex Synthesis
The diethylenetriamine pentaacetic acid dianhydride (DTPA-DA)
synthesis procedure has been described previously [18]. DTPA-DA
(3.57 mg) was dissolved in anhydrous DMF (10.0 ml) under a
steady ﬂow of N2, and then N, N-dicyclohexylcarbodiimide (DCC)
(4.5 mg), 1-hydroxy-benzotriazole (1.6 mg), triethylamine (2.0 ml),
and activated molecular sieve 3 Å (100 mg) were added to the
medium. The reaction mixture was stirred at RT for at least 30 min,
the reaction temperature increased to 100 °C, and then APTES
(1.0 mg) was added. The reaction mixture was heated at 100 °C for
24 h and ﬁnally, it was centrifuged (6,000 rpm, 25 min) and
redispersed in water to remove unreacted APTES. After washing
with water and ethanol, a white powder was obtained in high yield
(990 %). DTPA-DA: Fourier transform infrared spectroscopy (FT-
IR) (KBr, per centimeter): 906; 1,203; 1,089; 1,638; 2,927; and
3,380. MS: m/z %: 596.2. DTPA-APS: FT-IR (KBr, per centime-
ter): 1,638.53; 1,730.95; 1,818.49; 2,555.90; 2,714.65; and
3,103.84. MS (ESI negative ion): m/z 357.3 [M-H] for the
silanetriol from a basic solution. The schematic synthesis of
DTPA-DA is shown in Fig. S1.
Preparation of Si-DTPA-Gd3+ Complex
Si-DTPA (100.0 mg) dissolved in distilled water (4.0 ml) was
stirred at RT. A solution of GdCl3 (300.0 μl of a 0.5 M) was added
drop wise into the solution. The solution pH was adjusted to about
nine with addition of NaOH (1 M) [19]. After stirring for 3 h at RT,
the reaction mixture was dialyzed by using a dialysis bag (cut off
point 500–1,000 Da) against phosphate buffer solution (PBS) to
ensure the removal of unreacted Gd3+.
Synthesis
The schematic synthesis procedure of mono (3-aminopropyl
triethoxysilyl)diethylenetriamine pentaacetic acid (Si-DTPA) is
shown in Fig. S1. The Si-DTPA-Gd3+ complex were identiﬁed by
using ultraviolet spectroscopy (see Fig. S2).
Loading Si-DTPA-Gd3+ in MSN-NH2
The MSN-NH2 (200.0 mg) was reﬂuxed with a Si-DTPA-Gd
3+
complex (0.5 ml, 0.1 M) in anhydrous EtOH. The resulting
Gd3+-based MSN-NH2 (NH2-MSN-Gd
3+) was centrifuged at
8,000 rpm for 15 min then washed with water and ethanol
subsequently [2].
Carboxylic Acid-Functionalized MSN (COOH-
MSN-Gd3+)
A dispersion of NH2-MSN-Gd
3+ (553.0 mg) in anhydrous DMF
(20.0 ml) was added to succinic anhydride (200.0 mg in anhydrous
DMF). The mixture was stirred under N2 over night. The COOH-
MSN-Gd3+ was isolated by using centrifuge (6,000 rpm, 10 min),
and washed three times with DMF [20].
Synthesis of Met-MSN-Gd3+
A dispersion of COOH-MSN-Gd3+ (10.0 mg) in anhydrous DMF
was sonicated for 10 min. The coupling agent [DCC (0.2 mg)/
HOBT (0.1 mg)] was added to the solution and the reaction mixture
was stirred at RT for at least 30 min. Benzyl-carboxyl protected-
methionine (30.0 mg) was added and the reaction mixture was
stirred at RT for 72 h under N2. The reaction mixture rinsed with
DMF and water. The amino acid derivative was dissolved in 1:1
methanol/tert-Butyl alcohol. The Pearlman’s catalyst [Pd(OH)2-C]
was added under a hydrogen atmosphere and was allowed to stir
until completed. Unbounded methionine was removed by dialyzing
against PBS to ensure the removal of all free methionine. The
schematic synthesis of Met-MSN-Gd3+ is shown in Fig. S3.
Preparation of Fluorescent-Doped MSN (MSN-
FITC)
Rhodamine B isothiocyanate (5.0 mg) was dissolved in anhydrous
ethanol (20.0 ml) and 3-aminopropyltriethoxy silane (4.0 μl) was
added to the solution [21]. The reaction mixture was stirred at RT
in darkness for 24 h. MSN–NH2 (50 mg) was suspended in dried
toluene (5.0 ml) and then a solution of rhodamine-APS (100.0 μl,
6 mM) was added. The mixture was reﬂuxed overnight. MSN-NH2-
FITC was isolated by centrifuging, and washed with water and
ethanol twice. A dispersion of MSN-NH2-FITC (500.0 mg) in
anhydrous DMF (20.0 ml) was added to succinic anhydride
(200 mg in anhydrous DMF). The mixture was stirred under N2
over night. The MSN-COOH-FITC was isolated by centrifuge
(6,000 rpm, 10 min), and washed twice with anhydrous DMF. A
dispersion of MSN-COOH-FITC (5.0 mg) in anhydrous DMF
(20.0 mM) was sonicated for 15 min. The coupling agent [DCC
(1 mg)/HOBT (0.5 mg)] was added to the solution and the reaction
mixture was stirred at RT for 30 min in the dark. Benzyl-carboxyl
protected-methionine (15.0 mg) was added and the reaction mixture
was stirred at RT for 24 h under N2. After removing the benzyl
group, the reaction mixture was rinsed with DMF and then the Met-
MSN-FITC powder was obtained.
Cell Culture
Human breast cancer (MCF-7) and kidney (HEK 293) cell lines
cultured at 37 °C and 5 % CO2 by using standard cell culture
media, containing Dulbecco’s Modiﬁed Eagle Medium (DMEM).
The cell culture medium was supplemented with 10 % FBS and
1 % penicillin–streptomycin.
B. Mehravi et al.: Cancer Cells Imaging By a Targeting Nanoprobe 521
Cell Viability Test
For the MTT assay, the MCF-7 cell line (5×105 cells per well) was
incubated with various amounts of Met-MSN-Gd3+ (100, 50,
10 μg/ml), MSN-Gd3+ (100 μg/ml) and Magnevist (100 μg/ml) in
a 96-well microplate for 24 h with untreated cells as control. Each
concentration was tested in triplicate. The cells were washed with
PBS before adding MTT solution (20 μl of 5 mg/ml MTT solution)
to each well. After 4 h, absorbance of purple formazone was
measured by using BioTek’s absorbance microplate readers at
450 nm (Fig. 1).
Intra-cellular Uptake of Met-MSN-Gd3+
To detect intra-cellular uptake of Met-MSN-Gd3+ and MSN-Gd3+,
MCF-7 and HEK 293 cell lines were re-plated into 6-well plates at
a concentration of 1×105 cells per well and incubated at 37ºC and
5 % CO2 for 24 h. Met-MSN-FITC (ﬂuorescein isothiocyanate,
100 μM) was added to each well (1-ml media). Cells were
incubated at 37ºC and 5 % CO2 for 2 h, washed twice with PBS
(500 μL), and then centrifuged at 1,000 rpm for 4 min and
reconstituted in 100 μL of PBS. The intra-cellular ﬂuorescent
activity was counted and analyzed. The resulting labeled cells were
imaged using a ﬂuorescent microscope and analysis of quantitative
cell uptake was performed by ﬂow cytometer [19]. Finally, the
intra-cellular uptake of Gd3+ ions was determined by inductively
coupled plasma atomic emission spectroscopy (ICP-AES), quanti-
tatively. The measurements were performed in triplicate and the
mean ± SD of the results were calculated.
MR Measurement
The relaxation times of Met-MSN-Gd3+ were measured at different
concentrations by using different spin echo and gradient echo
protocols in 3T MRI with a head coil. For T2 measurement,
multiple spin echo protocols were used. In total, 32 echoes with an
echo spacing of 2 ms were obtained. The ﬁrst echo time (TE) was
13.2, TR was 3,000 ms, matrix=256×256; slice thickness=
1.5 mm, and non-averaged. A FLASH protocol was used to
calculate T1 maps. Repetition times of TR=20, 50, 100, 200, 400,
600, 1,000, 2,000 and 3,000 ms; TE was 12 ms; matrix=256×256;
slice thickness=1.5 mm, and non-averaged.
In Vitro MRI Preparation
The MCF-7 cell line (1×105) was incubated with different
doses of Met-MSN-Gd3+ (0.8, 0.4, and 0.2 mM) for 1 h. The
labeled cells were washed with PBS, trypsinized, and centri-
fuged at 1,000 rpm for 5 min at 37 °C. Subsequently, cells
were re-suspended in an equal volume of DMEM culture media
and 2 % agarose gel at 37 °C, and were immediately
transferred into the phantom tubes for MR procedure. The
relaxation rates were measured using 3 T MRI scanners. The
untreated cells were used as the control group. For quantitative
analysis, the MRI images were analyzed by DICOM software
version 1.3.0.5. (MEDAV GmbH Company).
In Vivo MRI Preparation
The murine mammary adenocarcinoma cells were trypsinized and
re-suspended in 10-fold excess culture medium. After centrifuga-
tion, cells were re-suspended in serum-free medium, and 1×106
cells injected subcutaneously in a ﬁnal volume of 0.1 ml using a
21-gauge needle in the left ﬂank of BALB/c mice under ketamine
and xylazine (10 mg/kg, i.p) anesthesia. Tumor growth was visible
2–3 weeks post injection. The tumor images were obtained 15 min




APTES was used to introduce amine groups on the surface
of MSN by silanization. The carboxylic acid group was
Fig. 1 MTT results of 48 h of Met-MSN-Gd3+, MSN-Gd3+, and Magnevist exposure to human breast cancer cell lines (MCF-7),
and human kidney cell lines (HEK-293), no significant toxic effect was observed (PG0.05).
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produced by a ring opening linker elongation reaction of
the amine group with succinic anhydride. These conver-
sions were qualitatively tested by salicylaldehyde. Upon
addition of salicylaldehyde, the MSN–NH2 (without
surfactant) was turned yellow immediately, indicating
the presence of amino groups, whereas observation
showed that extracted MSN–COOH was hardly yellow
even after 24 h. This indicated that most of the amino
groups were converted to COOH as reported by others
previously [20].
Nitrogen gas adsorption measurements indicated that the
surfactant-extracted MSN is highly porous with a surface
area of 1,189 m2/g and an average pore diameter of 2.5 nm
and total pore volume of 0.59 cm3/g. On the other hand,
Met-MSN-Gd3+ reduced surface area of 22.5 m2/g, a pore
diameter of 1.0–1.5 nm and total pore volume of 0.086 cm3/
g (see Table S1).
TGA analysis of extracted MSN showed a weight loss of
1.0% in the 160–290 °C temperature range. This result indicates
that the surfactant removed during extraction (see Fig. S4).
The modiﬁcation of mesoporous silica surface accom-
panied by a change in silica surface nanoparticle charge,
which was conﬁrmed by zeta potential measurements (see
Table S2). The MSN–NH2 nanoparticle aggregated in
water at pH value 7. In this study, the solution showed
alkalescence and a low negative zeta potential about
+3.7 mV, so MSN–NH2 aggregated in a short time [20–
23]. Pore size distribution of surfactant-extracted MSN and
MSN-Gd3+-Met are shown in Fig. S5.
Fourier transform infrared spectroscopy was used to
conﬁrm the existence of functionalized MSNs in the
region of 400–4,000 cm−1. The infrared spectrum of
MSN showed a broad absorption band at 3,200–
3,600 cm−1 corresponding to the silanol-OH bond and
Fig. 2 Intra-cellular uptake of MSN-Gd3+ and Met-MSN-Gd3+ by different techniques: ICP-AES (a), flow cytometry (b),
and fluorescent Microscopy (c). Notes: The insets show the purity of the cell populations, 1 × 105 MCF-7 cells in mL
media; Met-MSN-Gd3+ -labeling cell after 2 h. Results indicated the Methionine effect on intra-cellular uptake.
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strong absorption of the siloxane (Si−O−Si) group at
1,094 cm−1. When methionine was grafted onto the
MSNs, the spectrum showed a new broad absorption band
at 3,100–3,600 cm−1 corresponding to the carboxylic acid
(-COOH) bond and an absorption of the siloxane (Si−O
−Si) group at 1,062 cm−1. An amide carbonyl (−NH
−C=O) stretch mode at about 1,655 and 1,501 cm−1.
These results indicate that methionine was incorporated
into MSNs (see Fig. S6).
Scanning and transmission electron microscopy was
used to evaluate MSN morphology and size. The images
show that there was no change in MSN morphology after
conjugation of methionine onto the surfaces of the
MSNs, extraction of the surfactant, or upon grafting of
the Gd3+-DTPA-chelated molecule (see Fig. S7 and
S8).
The high-angle XRD patterns of MSN and Met-MSN-
Gd3+ are shown in Fig. S9. The MSN exhibits a single
strong peak in the XRD pattern followed by two additional
peaks which are assigned to the (100), (110), and (200)
reﬂections of a hexagonal lattice. The Met-MSN-Gd3+
sample displays the same reﬂections with a small peak shift
to the high angles.
The Cell Viability Test
Figure 1 shows a comparison of MCF-7 cell line incubated
for 24 h at different concentrations (10, 50, and 100 μg ml−1)
of Met-MSN–Gd3+, MSN–Gd3+ (100 μg ml−1), and
Magnevist (100 μg ml−1). The values for all Met-MSN-
Gd3+ concentrations were similar to control (untreated cells),
indicating that cell viability was not affected at the
concentration range, whereas Magnevist showed signiﬁcant
toxicity effects (PG0.05).
Intra-Cellular Uptake of Met-MSN-Gd3+ Into
Tumor Cells
Figure 2 shows the afﬁnity of tumor cells to the Met-
MSN-Gd3+ in comparison with the nonspeciﬁc precursor
MSN-Gd3+. Fluorescence microscopy as well as ﬂow
cytometry studies on tumor cells showed 23 %±0.09
intra-cellular uptake for nanospheres but a high intra-
cellular uptake ratio of 65.77 %±1.7 was obtained for
Met-MSN-Gd3+. Data conﬁrms the important role of
conjugate methionine in nanostructure of Met-MSN-
Fig. 3 The difference of intra-cellular uptake of Met-MSN-Gd3+ in human breast cancer cell lines (MCF-7) and normal kidney
cells (HEK-293).
Fig. 4 Effect of the addition of methionine to the incubation medium on the amounts of internalized Met-MSN-Gd3+ into MCF-
7 cell lines.
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Gd3+; these results were also conﬁrmed by ICP-AES
data.
To assess the in vitro capability of the Met-MSN-Gd3+ to
discriminate between tumor and normal cells (see cell
culture in Materials and Methods), an ICP-AES analysis
was carried out on MCF-7 and HEK-293 cell lines. Figure 3
shows that Met-MSN-Gd3+ intra-cellular uptake in human
breast cancer cell (MCF-7) was higher than that found in
human normal kidney cells (HEK-293). Figure S10 also
shows that cells labeled with Met-MSN-Gd3+ shows a more
intense signal on the T1-weighted spin echo image than the
unlabeled cells. This indicated efﬁcient uptake of the Met-
MSN-Gd3+ for cancer cell imaging.
To demonstrate the methionine graft on the surface of the
MSN-Gd3+ (as the vehicle for the internalization through the
amino acid transporting system), competition evaluations with
free methionine were carried out. Figure 4 shows that the intra-
cellular uptake of theMet-MSN-Gd3+ byMCF-7 cell decreases
as the concentration of the free methionine added to the culture
medium increases.
In Vitro MRI Experiments
To ﬁnd the enough amount of internalized Met-MSN-Gd3+ for
MRI visualization of cancer cells, an in vitro MRI experiment
Fig. 5 T2 data based on spin echo and gradient echo protocols (a). T1 data based on spin echo and gradient echo protocols
(b). The r1 and r2 relaxivity curves of Met-MSN-Gd
3+ in cancer cells by 3T scanner (c).
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was performed. For this purpose MCF-7 cells were incubated for
1 h in the presence of 100 μM of Met-MSN-Gd3+. Results show
that labeled cells with Met-MSN-Gd3+ displayed a strong and
intense signal on the T1-weighted spin-echo imagewith respect to
the untreated cells which demonstrates an efﬁcient uptake of the
Met-MSN-Gd3+. The r1 and r2 values were measured after cell
uptake by MRI, and found 11.65 and 22.33 mM−1 s−1 in cells,
respectively. Relaxometric investigations shows more insights
into the intra-cellular localization of Met-MSN-Gd3+. Figure 5
demonstrates the observed relaxation rates (R1) vs. the number of
Gd3+ ions per cell. On the basis of these results, the Met-MSN-
Gd3+ is considered for the following in vitro and in vivo studies.
Cancer Cell Imaging
For cell imaging, about 4×103 labeled cells and 4×103
unlabeled cells was injected in the right and left dorsal ﬂank
of mice, respectively. Figure S11 showed that the labeled
cells had very good signals after 10 min when compared to
the unlabeled cells.
In Vivo Targeting of Methionine Receptors
To evaluate the in vivo capability of the Met-MSN-Gd3+ and
discriminate between tumor and normal tissues, a MRI study
was carried out on animal models. Results indicated that the
tumor images was obtained a few minutes after the injection
and the amount of internalized Met-MSN-Gd3+ is large
enough to yield a signiﬁcant effect on the MRI signal
intensity (Fig. 6).
Statistical Analysis
Multi group comparisons were carried out by one-way
ANOVA. Statistical signiﬁcance for cell toxicity was set at
PG0.05. Results are expressed as mean ± SD.
Discussion
In the present study, we used MSN as a nanocarrier for
cancer imaging. The development of novel CAs that
accumulates at the target tissues is critical for cancer cell
imaging especially in MRI. Conjugation of methionine on
the surface of MSN can be used to increase the speciﬁc
accumulation of these nano carriers within the desired
cancerous tissue. Recent studies demonstrate that conjugat-
ing functional groups on the surface of MSN, can affect the
cell uptake of MSN. Most notably, D-glucose was conjugat-
ed to MSN and DTPA labeled with Gd3+, was investigated
in vitro and in vivo for human breast cancer cell imaging
[18, 24, 25]. In addition, a nano-dendrimer was synthesized
and conjugated with C595 MAb against human breast
cancer cells, followed by chelating agent with Gd3+ and
used as a dual-nanosized probe for detection and treatment
[26]. Other researchers have developed a reporter Gd3+-
DOTAMA-C6-Gln, where the glutamine residue was cova-
lently bound to the Gd3+ chelate through a C6 spacer as a
contrast agent for MRI [3].
It is cited that internalization of MSN is due to their
strong afﬁnity for clathrin-coated vesicles because of their
siliceous composition; clathrin pits have been identiﬁed as
the main mechanism of cell entry of non-cell membrane
integrity [25]. After grafting methionine on the MSN
surface, internalization occurs through a receptor-mediated
endocytosis. As a result they are internalized in to MCF-7
cells by speciﬁc cellular uptake and transported into the
cytoplasm based on up-regulation of methionine transport
system.
The surface charge property, zeta potential, of Met-MSN-
Gd3+ was −27.4 which showed that Met-MSN-Gd3+ with
high-surface charges can easily escape endosomal entrap-
ment. This phenomenon could be attributed to the osmotic
pressure produced by high density of ions surrounding the
surface of highly charged MSN [5]. To allow the interaction
Met-MSN-Gd3+ with the transporter on the cell membrane, it
is necessary to introduce an aliphatic spacer between the
Fig. 6 Breast cancer tumor imaging using MRI: pre-contrast (a) and 15-min post-contrast (5 μmol/kg) (b). This result shows the
ability of Met-MSN-Gd3+ in enhancing the T1-weighted liver images at lower doses.
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MSN and methionine moiety. In this procedure, the succinic
anhydride probably can cover the curved surface completely.
After reacting methionine with COOH, methionine can
cover the curved area. The accessibility of the methionine
on the surface is expected to be great for the curved surface
and exhibit great freedom of movement [25].
Other studies have also aimed at increasing CAs or
nanoparticles uptake by cancer cells by conjugating them
with methionine [11–13]. In one study, researchers conju-
gated methionine to DTPA and an anionic linear globular
dendrimer G2, which was labeled with 99mTc, and examined
cancer cell imaging in vitro and in vivo and also studied
cellular uptake of these components in the human colon
adenocarcinoma (HT 29) cell line. The results indicated that
the cellular uptake of 99mTc-DTPA-Met after 2 and 4 h were
about 22 and 43 %, respectively [11]. Our results indicated
that cellular uptake of Met-MSN-Gd3+ after 2 h was about
65.77 %±1.7. The cellular uptake was higher than 99mTc-
DTPA-Met and 99mTc-Dendrimer–Met. This difference is
probably related to nanoparticles properties (size, charge)
and cancer cell lines. Furthermore, increasing amounts of
free methionine in the culture medium clearly inhibits the
cellular uptake. These results helped to demonstrate that
methionine is the vehicle for the interaction of this contrast
agent with cancer cells.
The in vitro studies on human breast cancer cells such as
MCF-7 showed that Met-MSN-Gd3+ was taken up by cells
2–7 times more efﬁciently than the MSN-Gd3+which shows
the importance of methionine group in internalization of Met-
MSN-Gd3+. Another interesting point is the differential intra-
cellular uptake of methionine into cancerous and normal cells:
the amount of Met-MSN-Gd3+ in human breast cancer cells
was higher than that in normal kidney cells. This result
supports the methionine transporter up-regulation in cancer
cells and that internalization ofMet-MSN-Gd3+ occurs through
a receptor-mediated endocytosis [27].
Biocompatibility is a major concern when Met-MSN-
Gd3+ is introduced into cells. Results showed no signiﬁcant
changes in cells viability treated with Met-MSN-Gd3+
compared to control group (Fig. 1), while Magnevist showed
signiﬁcant cell toxicity. The results are consistent with our
previous studies that show Met-MSN is excellent contrast
agent delivery carrier [28].
Furthermore, since Met-MSN-Gd3+ is designed as a
contrast agent, relaxivities are essential parameters. The r1
and r2 values after intra-cellular uptake by MRI were found
11.65 and 22.33 mM−1 s−1 in cells, respectively, and the r2/
r1 ratio was 1.9. This result showed that Met-MSN-Gd
3+ is a
good T1-weighted contrast agent. We attributed the en-
hanced MR relaxivity to the accessibility of cellular water
molecules at Gd3+. Relaxometric investigations showed that
it is possible to get more insights into the intra-cellular
localization of Met-MSN-Gd3+. This is due to the endosomal
compartmentalization of water molecules that are an addi-
tional barrier for the Gd3+ to access water. Comparing the
relaxivities of Met-MSN-Gd3+ and Magnevist (r1 value of
4.1 mM−1 s−1 under the same condition) [2] show that the
Met-MSN-Gd3+ can be a better contrast agent than
Magnevist. A signiﬁcant positive signal enhancement in
the T1-weighted image was observed for the labeled cells
when compared to the unlabeled cells (Fig. S11). The T1-
weighted image enhancements were related to the reduction
of T1 relaxation times.
Moreover, in the present study, a tumor-oriented MR-
contrast agent based on Met-MSN-Gd3+ targeted to the
methionine receptors that are over expressed in tumor cells
has shown the ability of Met-MSN-Gd3+ in enhancing the
T1-weighted images. Other researcher also synthesized
MSNs, labeled with Gd3+-DTTA, as T1-contrast agent
without targeting group [2] and demonstrated the efﬁcacy
of MSN-Gd3+ as T1-contrast agents both in vitro and in vivo.
Our results conﬁrm the results that MSN-Gd3+ has good
potential in early cancer diagnosis [2]. The effectiveness of
Met-MSN-Gd3+ as an in vivo MR-contrast agent was
evaluated. The tumor images were obtained a few minutes
after tail vein injection of 5.0 μmol/kg/B.W of Met-MSN-
Gd3+, supporting the utility of Met-MSN-Gd3+ as a potential
intravascular MRI contrast agent. Clearly, targeting methio-
nine transporters with stable Met-MSN-Gd3+ appears to be
an efﬁcient route for improving diagnostic cancer in early
stage. Finally, the injected dose was lower than the amount
of contrast agents that are currently used (0.1–0.3 mmol/kg)
[3, 6, 9]. We attributed this to the large pore volume of
MSNs for pay-loading of Gd3+-Si-DTPA.
Conclusion
In summary, we have demonstrated that by attaching
methionine to the external surface of MSN, one can improve
the cellular uptake efﬁciency of MSN, as well as their ability
to escape endosomal compartments. These ﬁndings provide
helpful insights in the design of efﬁcient contrast agents for
nanocarriers delivery.
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